Related Experiment Video
Updated: May 31, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
Ivabradine in a Neonate With Severe Hypertrophic Cardiomyopathy
Yaa S Karikari1, Genevieve Baxter1, Hugo R Martinez2
1The University of Tennessee Health Science Center, Le Bonheur Children's Hospital, Memphis, Tennessee, USA.
Ivabradine effectively controlled heart rate (HR) in a neonate with severe hypertrophic cardiomyopathy (HCM) and Noonan syndrome. This treatment allowed for weaning of other medications and support, demonstrating its potential in pediatric HCM management.
Area of Science:
- Pediatric Cardiology
- Genetics
- Pharmacology
Background:
- Hypertrophic cardiomyopathy (HCM) impacts ~20% of Noonan syndrome patients, a major cause of mortality.
- Neonatal severe HCM with left ventricular outflow tract obstruction presents challenges in heart rate (HR) and systemic vascular resistance control.
- Standard therapies may exacerbate left ventricular outflow tract obstruction.
Related Concept Videos
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Heart Failure Drugs: Inotropic Agents
Cardiomyopathy II: Dilated Cardiomyopathy
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic Antagonists: ɑ and β-Receptor Blockers